GenAI Engineer
About the job
- A Master's degree with at least 4 years of relevant experience in Computer Science, Information Technology, Engineering, Data Science, or a related field, or a Bachelor's degree with at least 6 years of relevant experience in those fields.
- At least 4 years of professional experience in software development, application engineering, systems integration, or system design.
- At least 2 years of hands-on experience building, deploying, or supporting production GenAI applications, assistants, agents, Custom GPTs, RAG solutions, or comparable AI-enabled software.
- Strong hands-on proficiency in Python and experience developing, testing, debugging, and maintaining production applications, APIs, data services, or integration components.
- Hands-on experience with prompt and context design, embeddings, vector databases or search, retrieval pipelines, structured outputs, tool integration, agent orchestration, evaluation, guardrails, and observability.
- Experience designing and building cloud-native solutions, preferably on AWS, using services such as Amazon Bedrock, AWS Lambda, Amazon EKS or ECS, API Gateway, IAM, networking, monitoring, and event-driven integration.
- Experience designing secure RESTful or GraphQL integrations using API gateways, OAuth, service identities, enterprise authentication, role-based access, secrets management, and least-privilege principles.
- Experience with automated testing, source control, code review, Git-based workflows, CI/CD, and responsible use of AI-assisted software development tools.
- Experience building modern web applications using TypeScript, React, Next.js, component-driven architecture, state management, design systems, and API integration.
- Working knowledge of SQL, files, databases, and governed data-access patterns, with troubleshooting and analytical skills across application, model, data, integration, and infrastructure layers.
- Strong verbal and written communication skills and the ability to produce clear technical documentation.
- Ability to collaborate effectively with global, distributed, cross-functional teams using agile or scaled agile ways of working.
- Ability to deliver high-quality outcomes with appropriate guidance, manage multiple priorities, assess gaps and fit, communicate technical risks and tradeoffs, and support shared team outcomes.
- Design, develop, test, and deploy LLM-powered assistants, agents, Custom GPTs, RAG solutions, APIs, and AI-enabled applications on ChatGPT Enterprise and other approved platforms.
- Implement prompt and context strategies, structured outputs, embeddings, vector or hybrid retrieval, tool calling, workflow orchestration, and human-in-the-loop controls.
- Build scalable RAG pipelines that ground responses in trusted enterprise data.
- Contribute to the GenAI capability roadmap through implementation of MCP-based Apps, ChatGPT Skills, plugins, Workspace Agents, and reusable integration patterns.
- Develop integration layers and event-driven workflows using APIs, RPA, n8n, and approved orchestration tools to connect systems and trigger agent workflows.
- Develop reusable Python services, libraries, templates, and evaluation utilities, and contribute TypeScript, React, or Next.js components when required by the solution.
- Implement automated unit, integration evaluation, and end-to-end tests, along with tracing and monitoring for retrieval quality, response consistency, and reliability.
- Implement safeguards for prompt injection, data leakage, unauthorized retrieval, insecure tool execution, secrets exposure, excessive agency, and inappropriate model outputs.
- Apply secure integration and identity patterns using API gateways, OAuth, service identities, delegated authorization, role-based access control, secrets management, least privilege, and user-level auditability.
- Build and maintain CI/CD pipelines and approved cloud deployment configurations using AWS services, containers, serverless compute, or managed platform capabilities.
- Troubleshoot defects across application, model, retrieval, data, integration, and infrastructure layers; support incident investigation, remediation, rollback, patching, and performance tuning.
- Create and maintain technical designs, test evidence, runbooks, deployment instructions, and handover materials that support sustainable operations.
- Partner with functional teams, product owners, architects, business SMEs, data engineers, platform teams, DevOps, cybersecurity, privacy, and responsible AI stakeholders to translate requirements into reliable solutions.
- Participate in agile planning, backlog refinement, estimation, demonstrations, retrospectives, release activities, and technical design reviews.
- Review code and technical designs, apply software engineering standards, and use AI-assisted development tools such as OpenAI Codex or GitHub Copilot with appropriate review, security, and quality controls.
- Support office hours, technical enablement sessions, junior engineers, and knowledge-sharing through reusable examples, engineering patterns, and lessons learned.
- Communicate delivery status, technical risks, dependencies, defects, and recommendations clearly to technical and non-technical stakeholders.
- Experience with OpenAI APIs and SDKs, MCP servers and Apps, ChatGPT Skills, plugins, Workspace Agents, LangChain, LangGraph, n8n, or comparable agent technologies.
- Experience with Amazon Bedrock and related agent capabilities, AWS Lambda, Amazon EKS or ECS, Amazon EC2, API Gateway, IAM, VPC networking, or event-driven services.
- Experience with Databricks, Unity Catalog, Vector Search, SQL Warehouses, semantic layers, or governed natural-language-to-SQL solutions.
- Experience with Power Automate, UiPath, Tableau, Jira, Smartsheet, or comparable automation and delivery tools.
- Experience with model and application evaluation, red teaming, responsible AI, AI security, GxP, computer-system validation, regulated technology environments, or relevant technical certifications.
About the company
Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.
Company Size
10,001+
Company Stage
IPO
Headquarters
Thousand Oaks, California
Founded
1980
Get referred to Amgen
See people who can refer or advise you
Simplify's Take
What believers are saying
- Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
- Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
- Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.
What critics are saying
- Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
- MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
- Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.
What makes Amgen unique
- It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
- Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
- Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Conference Attendance Budget
Company News
Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.
Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.
Vertex Pharmaceuticals reported strong second-quarter results, with revenue rising 12% year-over-year to $3.33 billion and earnings per share climbing 8% to $4.31. The company posted positive Phase 2b results for inaxaplin, an experimental treatment for APOL1-mediated kidney disease, showing it reduced proteinuria in patients with modest protein levels and those with type 2 diabetes. Vertex expects approval for povetacicept, a treatment for IgA nephropathy, by November. The company continues diversifying beyond its core cystic fibrosis franchise, which provides predictable revenue as patients require lifelong treatment. Meanwhile, Amgen has also outperformed the broader market this year, though specific recent developments were not detailed in the source material.
Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.
Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.